

36. (Amended) A pharmaceutical composition comprising a peptide and/or antibody according to claims 1 and 23 together with one or more pharmaceutically acceptable carriers and/or diluents.
37. (Amended) A method of diagnosing or monitoring a condition in a mammal, which condition is characterised by an aberrant, unwanted or inappropriate response to Hev b 5, said method comprising screening for Hev b 5 reactive T cells and/or antibodies utilising the peptides according to claim 1.
39. (Amended) A method of qualitatively and/or quantitatively detecting Hev b 5, or peptides thereof, in a sample said method comprising screening for said Hev b 5 or peptides thereof utilising an antibody according to claim 23.
40. (Amended) A diagnostic kit for use in the method of claim 37.

REMARKS

The claims have been amended to remove multiple dependencies. As a result of the amendment, Claims 1-33 and 36-40 are presented for examination.

The changes made to the claims including [deletions] and insertions are shown on the attached sheet entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Preliminary Amendment.

Conclusion


Should there be any questions regarding the above-captioned patent application, the Examiner is respectfully requested to contact the undersigned at the telephone

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 25, 2002

By: 
Jennifer A. Haynes, Ph. D.
Registration No. 48,868
Agent of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

Please cancel claims 34-35.

Please amend the remaining claims as follows:

31. **(Amended)** An isolated nucleic acid sequence encoding or complementary to a sequence encoding the peptide according to any one of **[claims 1-22 or 27-30]**claim 1.
32. **(Amended)** A method for the treatment and/or prophylaxis of a condition in a subject, which condition is characterised by an aberrant, unwanted or otherwise inappropriate immune response to Hev b 5, said method comprising administering to said subject an effective amount of a peptide according to any one of **[claims 1-22 or 27-30]**claim 1 and/or an antibody according to **[any one of claims 23-26]**claim 23 for a time and under conditions sufficient to remove or reduce the presence or function in said subject of T cells and/or antibodies directed to said Hev b 5.
36. **(Amended)** A pharmaceutical composition comprising a peptide and/or antibody according to **[any one of claims 1-30]**claims 1 and 23 together with one or more pharmaceutically acceptable carriers and/or diluents.
37. **(Amended)** A method of diagnosing or monitoring a condition in a mammal, which condition is characterised by an aberrant, unwanted or inappropriate response to Hev b 5, said method comprising screening for Hev b 5 reactive T cells and/or antibodies utilising the peptides according to **[any one of claims 1-22 or 27-30]**claim 1.
39. **(Amended)** A method of qualitatively and/or quantitatively detecting Hev b 5, or peptides thereof, in a sample said method comprising screening for said Hev b 5 or peptides thereof utilising an antibody according to **[any one of claims 23-26]**claim 23.
40. **(Amended)** A diagnostic kit for use in the method of **[any one of claims 37-39]**claim 37 **[wherein said kit comprises a peptide and/or antibody according to any one of claims 1-30]**.